Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Open Label, Single Dose, Phase II Trial to Demonstrate the Safety of DWP-450 in Adult Subjects for Treatment of Moderate-to-severe Glabellar Lines

Next Previous
Search
Trial Profile

A Multi-center, Open Label, Single Dose, Phase II Trial to Demonstrate the Safety of DWP-450 in Adult Subjects for Treatment of Moderate-to-severe Glabellar Lines

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Glabellar lines
  • Focus Adverse reactions; Registrational
  • Acronyms EV-006
  • Sponsors Evolus

    • Most Recent Events

    • 23 Jan 2023 According to an Evolus media release, based on the safety and efficacy of Nuceiva from global TRANSPARENCY clinical program, which included two Phase III U.S. trials, the largest head-to-head aesthetic pivotal study versus BOTOX (onabotulinumtoxinA) to date, and two long-term safety studies, the Australian Therapeutic Goods Administration (TGA) has provided regulatory approval for Nuceiva for the temporary improvement in the appearance of moderate to severe glabellar lines in adult patients.
    • 12 May 2021 Results published in an Evolus Media Release
    • 12 May 2021 According to an Evolus media release, data from this trial were presented in the peer reviewed Aesthetic Surgery Journal.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top